215 related articles for article (PubMed ID: 9890698)
1. Palliative therapy in advanced ovarian cancer: balancing patient expectations, quality of life and cost.
Patnaik A; Doyle C; Oza AM
Anticancer Drugs; 1998 Nov; 9(10):869-78. PubMed ID: 9890698
[TBL] [Abstract][Full Text] [Related]
2. Resource implications of palliative chemotherapy for ovarian cancer.
Doyle C; Stockler M; Pintilie M; Panesar P; Warde P; Sturgeon J; Oza AM
J Clin Oncol; 1997 Mar; 15(3):1000-7. PubMed ID: 9060539
[TBL] [Abstract][Full Text] [Related]
3. Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer.
Doyle C; Crump M; Pintilie M; Oza AM
J Clin Oncol; 2001 Mar; 19(5):1266-74. PubMed ID: 11230467
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of early palliative care intervention in recurrent platinum-resistant ovarian cancer.
Lowery WJ; Lowery AW; Barnett JC; Lopez-Acevedo M; Lee PS; Secord AA; Havrilesky L
Gynecol Oncol; 2013 Sep; 130(3):426-30. PubMed ID: 23769759
[TBL] [Abstract][Full Text] [Related]
5. Quality of life in ovarian cancer patients choosing to receive salvage chemotherapy or palliative treatment.
Srisuttayasathien M; Khemapech N
Asian Pac J Cancer Prev; 2013; 14(12):7669-74. PubMed ID: 24460351
[TBL] [Abstract][Full Text] [Related]
6. Cost Effectiveness of Chemotherapeutic Agents and Targeted Biologics in Ovarian Cancer: A Systematic Review.
Poonawalla IB; Parikh RC; Du XL; VonVille HM; Lairson DR
Pharmacoeconomics; 2015 Nov; 33(11):1155-85. PubMed ID: 26072142
[TBL] [Abstract][Full Text] [Related]
7. Cost-minimisation analysis of pegylated liposomal doxorubicin hydrochloride versus topotecan in the treatment of patients with recurrent epithelial ovarian cancer in Spain.
Ojeda B; de Sande LM; Casado A; Merino P; Casado MA
Br J Cancer; 2003 Sep; 89(6):1002-7. PubMed ID: 12966416
[TBL] [Abstract][Full Text] [Related]
8. A cost-effectiveness analysis of chemotherapy for patients with recurrent platinum-sensitive epithelial ovarian cancer.
Case AS; Rocconi RP; Partridge EE; Straughn JM
Gynecol Oncol; 2007 Apr; 105(1):223-7. PubMed ID: 17215031
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of palliative chemotherapy in advanced gastrointestinal cancer.
Glimelius B; Hoffman K; Graf W; Haglund U; Nyrén O; Påhlman L; Sjödén PO
Ann Oncol; 1995 Mar; 6(3):267-74. PubMed ID: 7542021
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness studies in ovarian cancer.
Szucs TD; Wyss P; Dedes KJ
Int J Gynecol Cancer; 2003; 13 Suppl 2():212-9. PubMed ID: 14656283
[TBL] [Abstract][Full Text] [Related]
11. Paclitaxel: a pharmacoeconomic review of its use in the treatment of ovarian cancer.
Young M; Plosker GL
Pharmacoeconomics; 2001; 19(12):1227-59. PubMed ID: 11772158
[TBL] [Abstract][Full Text] [Related]
12. Symptom burden and outcomes of patients with platinum resistant/refractory recurrent ovarian cancer: a reality check: results of stage 1 of the gynecologic cancer intergroup symptom benefit study.
Friedlander ML; Stockler M; O'Connell R; Voysey M; Oza A; Gillies K; Donovan H; Martyn J; Sjoquist K; Butow P; King MT;
Int J Gynecol Cancer; 2014 Jun; 24(5):857-64. PubMed ID: 24844219
[TBL] [Abstract][Full Text] [Related]
13. Cost-effective treatment of women with advanced ovarian cancer by cytoreductive surgery and chemotherapy directed by an in vitro assay for drug resistance.
Orr JW; Orr P; Kern DH
Cancer J Sci Am; 1999; 5(3):174-8. PubMed ID: 10367175
[TBL] [Abstract][Full Text] [Related]
14. The costs and efficacy of liposomal doxorubicin in platinum-refractory ovarian cancer in heavily pretreated patients.
Hensley ML; Hoppe B; Leon L; Sabbatini P; Aghajanian C; Chi D; Spriggs DR
Gynecol Oncol; 2001 Sep; 82(3):464-9. PubMed ID: 11520141
[TBL] [Abstract][Full Text] [Related]
15. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
16. Recurrent ovarian cancer. Effective radiotherapeutic palliation after chemotherapy failure.
Corn BW; Lanciano RM; Boente M; Hunter WM; Ladazack J; Ozols RF
Cancer; 1994 Dec; 74(11):2979-83. PubMed ID: 7525039
[TBL] [Abstract][Full Text] [Related]
17. PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis.
Smith HJ; Walters Haygood CL; Arend RC; Leath CA; Straughn JM
Gynecol Oncol; 2015 Oct; 139(1):59-62. PubMed ID: 26303225
[TBL] [Abstract][Full Text] [Related]
18. Effect of delayed palliative chemotherapy on survival of patients with recurrent ovarian cancer.
Pyeon SY; Han GH; Ki KD; Lee KB; Lee JM
PLoS One; 2020; 15(7):e0236244. PubMed ID: 32701994
[TBL] [Abstract][Full Text] [Related]
19. Development of the measure of ovarian symptoms and treatment concerns: aiming for optimal measurement of patient-reported symptom benefit with chemotherapy for symptomatic ovarian cancer.
King MT; Stockler MR; Butow P; O'Connell R; Voysey M; Oza AM; Gillies K; Donovan HS; Mercieca-Bebber R; Martyn J; Sjoquist K; Friedlander ML
Int J Gynecol Cancer; 2014 Jun; 24(5):865-73. PubMed ID: 24844220
[TBL] [Abstract][Full Text] [Related]
20. Aggressive management of recurrent ovarian cancer--the challenge of individualizing cancer therapy illustrated by a case report.
Kieback DG; Einzmann T; Labinsky E; Fischer DC; Niebergall H; Hasenburg A
Onkologie; 2004 Aug; 27(4):393-7. PubMed ID: 15347897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]